Login to Your Account

In The Clinic NEWS

The race to relief for peanut allergy sufferers pounded onward Tuesday, with Aimmune Therapeutics Inc. delivering endpoint-meeting outcomes from a pivotal phase III test of its oral immunotherapy, AR-101

AUSTIN, Texas – Roswell Park Cancer Center is about to form a 50:50 joint venture (JV) with Cuba's Center for Molecular Immunology (CIM) to commercialize cancer vaccines developed by CIM.

A mid-stage trial testing the Galmed Pharmaceuticals Ltd. candidate aramchol (arachidyl amido cholanoic acid) over 12 weeks found it made no apparent difference in liver fat for people with HIV-associated lipodystrophy and non-alcoholic fatty liver disease (NAFLD). 

More In The Clinic Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: